- Home
- XBIT vs IPHA Comparison
XBIT vs IPHA Comparison
Compare XBIT & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XBIT | IPHA |
|---|---|---|
| Founded | 2005 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.2M | 174.2M |
| IPO Year | 2015 | 2019 |
Fundamental Metrics
Financial Performance| Metric | XBIT | IPHA |
|---|---|---|
| Price | $2.47 | $1.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | ★ 62.5K | 25.6K |
| Earning Date | 11-12-2025 | 09-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $14,839,695.00 |
| Revenue This Year | N/A | $22.29 |
| Revenue Next Year | N/A | $43.90 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.09 | $1.60 |
| 52 Week High | $5.11 | $2.63 |
Technical Indicators
Market Signals| Indicator | XBIT | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 51.08 | 36.12 |
| Support Level | $2.40 | $1.64 |
| Resistance Level | $2.55 | $1.81 |
| Average True Range (ATR) | 0.12 | 0.08 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 28.57 | 18.75 |
Price Performance
Historical ComparisonAbout XBIT XBiotech Inc.
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-inflammatory therapeutic antibodies as a treatment for cancer. Geographically, all of its operations are in the United States.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.